Uganda Heart Institute, is a specialized, public, tertiary care medical facility owned by the Uganda Ministry of Health. It is a component of Mulago National Referral Hospital, the largest hospital in Uganda, which serves as the teaching hospital of Makerere University College of Health Sciences.

There are 200 (Planned) beds in Uganda Heart Institute.

During the past decade, Uganda Heart Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uganda Heart Institute" #1 collaborator was "Uganda Heart Institute" with 4 trials as a collaborator, "Al Saha Specialised Hospital, Sudan" with 1 trials as a collaborator, "Al Shaab Teaching Hospital, Sudan" with 1 trials as a collaborator, "Aliaa Specialist Hospital, Sudan" with 1 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Uganda Heart Institute" are "Rheumatic Heart Disease" (3 trials), "Heart Failure" (1 trials), "Myocardial Reperfusion Injury" (1 trials), "Remote Ischaemic Conditioning" (1 trials) and "STEMI" (1 trials). Many other conditions were trialed in "Uganda Heart Institute" in a lesser frequency.

Most popular intervention types in "Uganda Heart Institute" are "Drug" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Community Awareness campaign" (1 trials), "Healthcare provider education" (1 trials), "Penicillin G Benzathine" (1 trials), "Remote Ischaemic Conditioning (RIC)" (1 trials) and "Rivaroxaban (20 mg)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Uganda Heart Institute" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Uganda Heart Institute". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Uganda Heart Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Uganda Heart Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".